Since the patients in the Liévin et al. study had G-CSF use similar to our study’s control group, it could be a benchmark for comparison: Our control group had a similar rate of CRS (74% vs. 73%, respectively), but a higher rate of ICANS (37% vs. 26%, respectively) [26]. The gene discussed is CSF3; the disease is congenital rubella syndrome.